• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Proteus Biomedical nabs CE Mark for ingestible sensor

Proteus Biomedical nabs CE Mark for ingestible sensor

August 13, 2010 By MassDevice staff

Proteus Biomedical logo

European Union doctors may now begin prescribing Proteus Biomedical Inc.’s “Raisins.”

The Redwood City, Calif.-based company won CE Mark approval for its ingestible “Raisin” sensor and personal physiologic monitor system.

Proteus also announced ISO 13485:2003 certification for the system, according to a press release.

The device has the ability to record any "discrete event," such as the ingestion of a specific pharmaceutical, along with other physiologic information such as heart rate and body angle. That information is then sent to a Bluetooth-enabled device, such as a smartphone, for mHealth applications, according to the company.

In April, Proteus won 510(k) clearance from the Food & Drug Administration for a wearable wireless monitor in the Raisin product family.

The company is also heralding the appointment of Arna Ionescu as director of product development and user experience. Ionescu is the former connected health domain lead of the IDEO design firm and will head Proteus’ new user experience group.

Filed Under: Business/Financial News, Diagnostics, Digital Health, News Well Tagged With: Proteus Digital Health

More recent news

  • Siemens Healthineers completes $44M R&D, manufacturing site expansion
  • Next-gen Apple Watch Ultra 4 includes new health features
  • Johnson & Johnson wins CE mark for new reusable contact lens and other extra medtech news
  • Zimmer Biomet plans to cut 580 jobs in Switzerland
  • Verily Health secures investment from Nvidia to advance healthcare AI platforms

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy